Cancer is a genetic disease caused by genetic instability. Our program in cancer genetics includes a component that emphasizes high throughput refined karyotypic analysis and comprehensive cloning and characterization of all chromosomal aberrations found to be present in specific cancers or cancer cell lines. We have dubbed an aspect of this approach, spectral cloning. Another major component involves the development of a patient pathway that emphasizes individualized risk screening, education, counseling, germline testing (for those who choose to be tested), followed by entry into protocols for prevention, surveillance, and targeted therapy. The two prototype cancers for which this program has been initiated are colorectal and breast cancer. In addition, in the coming yuear we plan on beginning a program focused on the genetics of smoking cessation. The translational research component that supports this program includes mulecular diagnostics, biomarkers of risk, genotype/phenotype correlations, and new drug screening assay invention. In addition, we are invested in new initiatives that are attempting to link the human physical genomic map with the cytogenetic map, and to provide a database and clone repository that can be utilized by the biomedical community at large. - genetics, - Human Subjects & Human Tissues, Fluids, Cells, etc.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007265-05
Application #
6290793
Study Section
Special Emphasis Panel (M)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Roschke, Anna V; Lababidi, Samir; Tonon, Giovanni et al. (2005) Karyotypic ""state"" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A 102:2964-9
Calzone, Kathleen A; Prindiville, Sheila A; Jourkiv, Oxana et al. (2005) Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. J Clin Oncol 23:3455-64
Hadley, Donald W; Jenkins, Jean F; Dimond, Eileen et al. (2004) Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 22:39-44
Junicke, Henrik; Hart, Jonathan R; Kisko, Jennifer et al. (2003) A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition. Proc Natl Acad Sci U S A 100:3737-42
Roschke, Anna V; Tonon, Giovanni; Gehlhaus, Kristen S et al. (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63:8634-47
Hadley, Donald W; Jenkins, Jean; Dimond, Eileen et al. (2003) Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med 163:573-82
Hausner, P; Venzon, D J; Grogan, L et al. (1999) The ""comparative growth assay"": examining the interplay of anti-cancer agents with cells carrying single gene alterations. Neoplasia 1:356-67